DA Davidson raised its price target on Paysign (NASDAQ:PAYS) to $8 from $7 while reaffirming a Buy rating, following a major boost to the company’s plasma donation center footprint.
Paysign recently announced the addition of 132 established plasma centers through an expanded partnership with a key plasma collection provider. This expansion brings the company’s total to 613 locations, up 27% from the 484 centers it serviced at the close of the first quarter of 2025.
In response to this growth, the firm revised its financial outlook upward for both 2025 and 2026 and initiated forecasts for 2027. The increase in plasma center coverage signals stronger future revenue potential and supports continued confidence in Paysign’s business trajectory.